Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clostridium difficile.

Bethan Stoddart1, Mark H Wilcox

  • 1Department of Microbiology, The General Infirmary and University of Leeds, UK.

Current Opinion in Infectious Diseases
|April 11, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study.

The Lancet. Infectious diseases·2026
Same author

Two concurrent nationwide healthcare-associated outbreaks of <i>Burkholderia cepacia</i> complex linked to product contamination, UK and Ireland, 2010-2023 - ADDENDUM.

Infection control and hospital epidemiology·2025
Same author

Understanding the impact of different hand drying methods on viral aerosols formation and surface contamination in indoor environments.

Frontiers in public health·2025
Same author

Clostridioides difficile pathogenesis and control.

Nature reviews. Microbiology·2025
Same author

Two concurrent nationwide healthcare-associated outbreaks of <i>Burkholderia cepacia</i> complex linked to product contamination, UK and Ireland, 2010-2023.

Infection control and hospital epidemiology·2025
Same author

Making Sense of Differing Guidelines for Clostridioides difficile Infection.

Infectious disease clinics of North America·2025
Same journal

Use of gloves: current evidence vs. current use.

Current opinion in infectious diseases·2026
Same journal

Understanding challenges to prevention of healthcare related infections.

Current opinion in infectious diseases·2026
Same journal

Harnessing next-generation microbial diagnostics to optimize infection management in immunocompromised hosts.

Current opinion in infectious diseases·2026
Same journal

Epidemiology, treatment and outcomes of antimicrobial-resistant infections in hematopoietic stem cell transplant recipients.

Current opinion in infectious diseases·2026
Same journal

Dengue and chikungunya vaccines past, present and future: implications for travelers.

Current opinion in infectious diseases·2026
Same journal

Oropouche virus: viral evolution, epidemiological trends, and challenges for control.

Current opinion in infectious diseases·2026
See all related articles

Clostridium difficile infection causes antibiotic-associated diarrhea. New treatments and vaccines are being developed due to rising resistance to metronidazole, the current standard treatment.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Clostridium difficile is a leading cause of antibiotic-associated diarrhea.
  • Broad-spectrum antibiotics are frequently implicated, with shorter courses causing fewer episodes.
  • Toxin A-negative, toxin B-positive strains are virulent, challenging diagnostic accuracy.

Purpose of the Study:

  • To review current understanding and treatment of Clostridium difficile infection.
  • To explore emerging therapeutic strategies and preventative measures.
  • To highlight advancements in diagnostics and understanding of C. difficile pathogenesis.

Main Methods:

  • Review of existing literature on Clostridium difficile infection.
  • Comparison of diagnostic assays (cell-culture vs. immunoassays).

Related Experiment Videos

  • Analysis of treatment outcomes and emerging therapies.

    • Main Results:

    • Metronidazole remains the primary treatment for C. difficile infection.
    • Alternative strategies like toxin-binding polymers and biotherapy are under development.
    • Immunization via a toxoid vaccine shows promise for preventing recurrence.

    Conclusions:

    • Clostridium difficile infection poses a significant public health challenge.
    • Development of novel treatments and preventative strategies is crucial due to resistance concerns.
    • Vaccine development offers a promising future for C. difficile prevention.